Rhenman & Partners Asset Management AB Sells 88,000 Shares of Gilead Sciences, Inc. $GILD

Rhenman & Partners Asset Management AB lessened its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 52.3% in the third quarter, according to its most recent filing with the SEC. The firm owned 80,150 shares of the biopharmaceutical company’s stock after selling 88,000 shares during the quarter. Rhenman & Partners Asset Management AB’s holdings in Gilead Sciences were worth $8,897,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Csenge Advisory Group boosted its holdings in shares of Gilead Sciences by 319.0% during the 3rd quarter. Csenge Advisory Group now owns 21,394 shares of the biopharmaceutical company’s stock worth $2,375,000 after buying an additional 16,288 shares in the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management boosted its stake in Gilead Sciences by 52.1% during the third quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 78,494 shares of the biopharmaceutical company’s stock worth $8,713,000 after acquiring an additional 26,882 shares in the last quarter. Cookson Peirce & Co. Inc. increased its stake in Gilead Sciences by 249.1% in the third quarter. Cookson Peirce & Co. Inc. now owns 10,045 shares of the biopharmaceutical company’s stock valued at $1,115,000 after purchasing an additional 7,168 shares in the last quarter. Railway Pension Investments Ltd boosted its position in shares of Gilead Sciences by 3.1% during the 3rd quarter. Railway Pension Investments Ltd now owns 1,415,665 shares of the biopharmaceutical company’s stock worth $157,139,000 after purchasing an additional 42,200 shares in the last quarter. Finally, TriaGen Wealth Management LLC acquired a new position in Gilead Sciences during the 3rd quarter worth approximately $1,274,000. Institutional investors own 83.67% of the company’s stock.

Insider Activity

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $144.79, for a total value of $1,447,900.00. Following the completion of the transaction, the chief executive officer directly owned 642,308 shares in the company, valued at approximately $92,999,775.32. This trade represents a 1.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $123.50, for a total transaction of $617,500.00. Following the transaction, the director directly owned 8,920 shares of the company’s stock, valued at approximately $1,101,620. This represents a 35.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 309,280 shares of company stock valued at $43,935,470. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Price Performance

NASDAQ GILD opened at $144.08 on Friday. The company has a market cap of $178.86 billion, a PE ratio of 21.28, a price-to-earnings-growth ratio of 1.89 and a beta of 0.37. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98. The firm’s 50-day simple moving average is $138.29 and its two-hundred day simple moving average is $125.80. Gilead Sciences, Inc. has a 52 week low of $93.37 and a 52 week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The company had revenue of $7.93 billion for the quarter, compared to analysts’ expectations of $7.68 billion. During the same period in the prior year, the company posted $1.90 EPS. Gilead Sciences’s revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be given a dividend of $0.82 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 annualized dividend and a dividend yield of 2.3%. The ex-dividend date is Friday, March 13th. Gilead Sciences’s dividend payout ratio (DPR) is currently 46.68%.

Wall Street Analysts Forecast Growth

GILD has been the topic of a number of research reports. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a research report on Thursday, January 22nd. UBS Group upped their target price on shares of Gilead Sciences from $145.00 to $155.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Sanford C. Bernstein reissued an “outperform” rating and set a $160.00 price objective on shares of Gilead Sciences in a report on Wednesday, February 11th. Citigroup reissued a “buy” rating on shares of Gilead Sciences in a research report on Friday. Finally, Morgan Stanley increased their target price on shares of Gilead Sciences from $150.00 to $171.00 and gave the company an “overweight” rating in a report on Wednesday, February 11th. Twenty-three equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average target price of $156.72.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.